Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Skin Neoplasms 1Metastatic gpNMB Expressing Triple Negative Breast Cancer 1Melanoma 1

Interventions

pembrolizumab 15Nivolumab 10Ipilimumab 7cemiplimab 6dabrafenib 4binimetinib 4Dacarbazine 4trametinib 3encorafenib 3Drug Therapy 3Allovectin-7 3zanolimumab 2talabostat 2lifileucel 2aldesleukin 2Vemurafenib 2Tablets 2Semaxinib 2Intravital Microscopy 2Interleukin-2 2Fluorouracil 2vitespin 1veliparib 1varlilumab 1tozuleristide 1tin etiopurpurin 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Neoplasms × glembatumumab vedotin × Clear all
NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡